Mirada Medical To Showcase Innovative Oncology Imaging Software Portfolio At RSNA Annual Meeting
Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced recently that it will be showcasing and launching new oncology imaging software designed to significantly improve productivity and communication between clinical specialists at the 2010 RSNA (Radiological Society of North America) trade show in Chicago, Illinois from November 28 - December 3, 2010.
At the conference, Mirada will launch its novel solution for presenting image based patient case information at specialist meetings such as tumor boards, multi-disciplinary team (MDT) meetings and radiology rounds. Users of Mirada's technology will be able to greatly reduce the time spent preparing multiple patient cases for presentation to the meeting, and will also benefit during the meeting from having instant access to the advanced visualisation and quantification features normally only available to the diagnostic reader.
Mirada will also be demonstrating the unique oncology fusion workflows of its XD3 image analysis software, including new CT, MR, PET/CT and MR/PET analysis tools designed to enhance speed and accuracy across the complete spectrum of imaging tasks, from diagnosis and staging through to treatment response assessment and follow-up.
The new tools, coupled with Mirada's industry leading deformable registration technology and built-in support for standard and user-defined response assessment protocols such as RECIST, WHO and PERCIST, give the user exceptional power to review, compare and quantify a patient's complete set of current and previous imaging studies.
Mirada's team will be available to demonstrate how the referring physician can now have access to rich web-based fusion viewing capabilities, allowing them to view PET/CT, MR-PET and even CT-MR-PET fused images, reports and findings that the reading radiologist or nuclear medicine clinician has sent.
Mirada's technologies are developed by world renowned scientists and dedicated engineers and the Company is focused on providing users with oncology imaging solutions to enhance their workflow whilst optimising the most accurate and consistent reporting and quantitative knowledge share in the multi-modal diagnosis and treatment of cancer.
Hugh Bettesworth, CEO of Mirada Medical, said: "We look forward to launching the final piece of our innovative suite of oncology imaging applications which, together, will offer not only the most advanced workflows in quantified diagnostic analysis of multi-modal images, but also significantly improve productivity and communication of findings when delivering these findings to the referring physician or presenting at specialist meetings such as tumor board. Mirada remains committed to the delivery of high quality healthcare solutions to its global customer base through the use of leading technologies."
Mirada Medical will showcase its latest and industry leading developments at Booth 7520, Hall B, North Building of McCormick Place.
About Mirada Medical
Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical's technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada's advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient's condition. Mirada's products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.
Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world's leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada's products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.
The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information, visit www.mirada-medical.com.
About RSNA
Founded in 1915, the Radiological Society of North America is a professional membership society committed to excellence in patient care through education and research. More than 40,000 medical imaging professionals are members of RSNA, including radiologists, radiation oncologists, medical physicists and allied scientists.
RSNA hosts the world's largest annual radiology meeting, publishes two highly respected peer-reviewed journals, offers opportunities to earn CME, and provides research and education grants to young investigators. For more information, visit www.rsna.org
SOURCE: Mirada Medical Limited